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Aim: The aim of this work is to evaluate rectal and bladder dose for the patients treated for
gynecological cancers.
Background: The GZP6 high dose rate brachytherapy system has been recently introduced
to  a number of radiation therapy departments in Iran, for treatment of various tumor sites
such as cervix and vagina.
Materials and methods: Our analysis was based on dose measurements for 40 insertions in
28  patients, treated by a GZP6 unit between June 2009 and November 2010. Treatments
consisted of combined teletherapy and intracavitary brachytherapy. In vivo dosimetry was
performed with TLD-400 chips and TLD-100 microcubes in the rectum and bladder.
Results: The average of maximum rectal and bladder dose values were found to be 7.62 Gy
(range 1.72–18.55 Gy) and 5.17 Gy (range 0.72–15.85 Gy), respectively. It has been recom-
mended by the ICRU that the maximum dose to the rectum and bladder in intracavitary
treatment of vaginal or cervical cancer should be lower than 80% of the prescribed dose to
point  A in the Manchester system. In this study, of the total number of 40 insertions, maxi-
mum  rectal dose in 29 insertions (72.5% of treatment sessions) and maximum bladder dose
in  18 insertions (45% of treatments sessions) were higher than 80% of the prescribed dose
to  the point of dose prescription.
Conclusion: In vivo dosimetry for patients undergoing treatment by GZP6 brachytherapy sys-tem can be used for evalu
This information could be
treated with GZP6 system
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.  Background
ecently a GZP6 high dose rate afterloading unit, with 60Co
ources, manufactured by the Nuclear Power Institute of China
NPIC),1 has been introduced to the radiotherapy centers
f Iran. The GZP6 brachytherapy unit uses six 60Co source
raids in six channels, as described in one of our previous
ublications.2 These units are utilized for treatment of cancers
f the cervix, rectum, esophagus and nasopharynx.2 Unlike
92Ir sources, the 60Co has a relatively higher half life and
ower speciﬁc activity, which makes it unfavorable as an high
ose rate (HDR) source. However, higher exposure rate con-
tant of 60Co (13.2 Rcm2/mCi h versus 4.69 Rcm2/mCi h) and
arger source size, multiple source versus a single source,
ompensate some of the deﬁciencies.3 Moreover, a longer
alf life source reduces the need for frequently changing the
ource, which is an advantage for some countries such as Iran.
his isotope has advantage in those countries where various
ources are not commercially and widely available. Besides,
0Co sources have higher air kerma rate constant than other
rachytherapy sources.
The rectum and bladder are two radiosensitive organs
djacent to the target volume in patients who are treated
or vaginal or cervical cancers.4 It is recommended that the
ose received by these organs during therapeutic sessions
hould be identiﬁed.5 The International Commission of Radi-
tion Units and Measurements (ICRU) in its report number 38
ecommended clear deﬁnition of the rectum and bladder ref-
rence points in the implemental procedures. The rectum and
ladder dose in reference to point A dose should be limited to
0% of prescribed point A dose based on the recommendations
f the report.5
There are various studies on TG-43 dosimetric evaluation
f the parameters, as well as tabulated dose rate distribu-
ions of GZP6 sources.6–9 Mesbahi et al. have evaluated radial
ose function for three GZP6 brachytherapy 60Co sources. They
ave compared the Monte Carlo calculated radial dose func-
ion values with those obtained from GZP6 treatment planning
ystem and their results have shown that there is a good
greement between the Monte Carlo and treatment planning
ystem values, except for points close to the source.6 Mes-
ahi and Naseri have calibrated three GZP6 sources through
n in-air measurement of air kerma rate. They have compared
ir kerma rate values obtained from measurement with those
rovided by the GZP6 manufacturer. The manufacturer pro-
ided air kerma rate values at 1 m distance were 6.195, 6.78
nd 5.44 cGy/s for sources 1, 2 and 3, respectively. The cor-
esponding measured air kerma rate values were 6.18, 6.95,
.58 cGy/s. The measured data for all the three sources were in
greement with the data provided by the GZP6 manufacturer.7
ahreyni et al. have determined air kerma strength of a GZP6
ource through Monte Carlo simulation and measurement and
ZP6 treatment planning system. When considering the large
ncertainty incorporated with the GZP6 treatment planning
alue, the air kerma strength values determined by the three
2ethods were in agreement. Naseri and Mesbahi have ver-
ﬁed dose distribution of GZP6 treatment planning system
hrough simulation of three GZP6 sources. In their study, the
ose distributions calculated by the GZP6 treatment planningtherapy 1 7 ( 2 0 1 2 ) 352–357 353
system were validated, but at the points near the sources
and beyond the tip of the sources the agreement between
the Monte Carlo and GZP6 treatment planning results was
not good.8 Hariri Tabrizi et al. have derived TG-43 parame-
ters for GZP6 sources in a comprehensive Monte Carlo study
of the sources. Their results can be used for validation of the
GZP6 treatment planning system and also for introduction
of a complementary software for this system.9 However, the
GZP6 treatment planning system still performs the treatment
planning based on Sievert integral and there are several pre-
ﬁxed treatment plans with predesigned dwell positions and
dwell times in tandem and ovoids for gynecological implants.
Therefore, a clinical application of these units requires in vivo
dosimetry for a more  accurate evaluation of dose received by
normal organs at risk, for patients who are being treated by
this system.
Despite a detailed dosimetric evaluation of the GZP6 sys-
tem with the most recently available recommendations by
the American Association of Physicists in Medicine (AAPM)
task group No. 43 (TG-43) report,10 there had been no clini-
cal available on this system at the time that this study began.
Particularly, for the pre-ﬁxed plans, knowing the bladder and
rectal dose arising from intracavitary treatments of cervical
cancers by this unit would be useful for clinical evaluation of
the unit.
2.  AIM
The goal of the present investigation is to present the retro-
spective evaluation of the measured bladder and rectal dose in
40 intracavitary brachytherapy procedures in 28 patients with
cervical or vaginal cancer who underwent treatment by a GZP6
60Co afterloading unit, between June 2009 and November 2010.
This report will provide a guideline for our future procedures.
3.  Materials  and  methods
3.1.  Patients
These investigations include a total number of 40 intracav-
itary brachytherapy procedures that were performed on 28
patients with cervical or vaginal cancers. These patients had
undergone a combined external beam radiotherapy and HDR
brachytherapy with a GZP6 afterloading unit at the Reza Radio-
therapy and Oncology Center, in the period between June 2009
and November 2010. The measurements of rectal and bladder
doses on these patients were performed using TLD. All the
intracavitary HDR treatments were performed under general
or partial anesthesia depending on the patients’ situations.
In accordance with the guidelines of our institutional ethical
committee, written consent of patients were obtained before
measurements were carried out. In these investigations, coor-
dinates of dose prescription point for each patient were based
on the anatomy of the patient and extent of the disease. Fig. 1
shows the schematic diagram of the applicator, prescription
points, and other points of interest in cases of cylindrical
applicator, pair ovoids and a tandem plus two ovoids. The ori-
gin of the coordinate system for each applicator combination
is also evident in this ﬁgure.
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Fig. 1 – A diagram illustrating prescription point (P) which was the point of dose prescription for the cases of: (a) cylinder, (b)
pair ovoids and (c) tandem plus two  ovoids in this study. There can be a number of other points of interest (P1, P2) in each
case.3.2.  TLD  calibrations
All TLDs (TLD-400 chips used for the rectum and TLD-100
microcubes used for the bladder dosimetry) were calibrated
in 10 × 10 cm2 ﬁelds of a Theratron Phoenix cobalt telether-
apy machine. The TLDs were positioned at 0.5 cm depth in a
cubic 20 cm × 20 cm × 10 cm Perspex phantom in the calibra-
tion process. The calibration was performed for dose of 1 Gy
and in the next step dose response of the TLDs was evaluated
for 1–20 Gy and 1–11 Gy dose ranges, respectively for TLD-
400 chips and TLD-100 microcubes. The output of the cobalt
unit was regularly calibrated by a 0.6 cc farmer type ionization
chamber (model NE 2581). Calibration procedure consisted of
three stages to determine ECC (element correction coefﬁcient)
and RCF (reader correction factor).
The TLDs were read by a Harshaw TLD reader (model
3500) 24 h after irradiation. Standard time temperature proﬁle
Fig. 2 – Dose–response (given dose (Gy) versus measured dose (G
microcubes used in this study.(TTP) deﬁned for reading of TLD-100 and TLD-400 chips were
applied. The annealing process of TLDs was performed at
400 ◦C for 1 h followed by a 2 h heating at 100 ◦C.
3.3.  In  vivo  measurements
A pilot study for a number of patients with respect to mea-
surement of rectum dose by TLD-100 chips showed that
there are cases in which the rectum dose measured by the
TLDs are higher than 10 Gy value which is the upper dose
limit for this type of TLDs. However, TLD-400 (CaF2:Mn)
has a linear response and can be used for a wider dose
range (0.1 Gy–100 Gy) to respond to low dose as well as
high dose values. Hence, TLD-400 (Harshaw/Bicron, Solon,
OH) with 3.2 mm × 3.2 mm × 0.9 mm dimensions was used for
rectum dose measurements. According to our pilot study,
the bladder dose was not high and therefore microcubes
y)). (a) For the TLD-400 chips and (b) for the TLD-100
reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 352–357 355
Table 1 – The measured maximum rectum and bladder dose values (in Gy). The dose values are also presented relative to
the prescribed dose. All of the distances are presented in cm.
Type of
applicators
Insertion
number
Diameter of
cylinder (cm)
Stepping
length (cm)
Prescribed
dose (Gy)
Prescription
point (x, y, z)
Rectum
dose (Gy)
Bladder
dose (Gy)
Maximum Relative Maximum Relative
Cylinder 1  3 5.5 5 2, 3, 0 3.95 79.02 3.70 74.06
2 2.5 5 5 1.75, 2.5, 0 3.16 63.20 7.86 157.26
Type of
applicators
Insertion
number
Size of
ovoids
Prescribed
dose (Gy)
Prescription
point (x, y, z)
Rectum
dose (Gy)
Bladder
dose (Gy)
Maximum Relative Maximum Relative
Pair
ovoids
3  Small 6 0.5, 0, 0 2.20 36.67 0.72 11.99
4 Small 6 0.5, 0, 0 1.72 28.68 1.19 19.87
5 Small 5 2, 2, 0 3.42 68.48 9.64 192.89
6 Small 5 2, 2, 0 10.87 217.47 7.95 159.00
7 Small 5 1, 1, 0 7.54 150.82 2.35 46.94
8 Small 5 1, 1, 0 7.02 140.44 2.08 41.53
9 Medium 6 2, 2, 0 9.91 165.09 10.40 173.34
10 Medium 6 1, 1, 0 2.03 33.75 3.17 52.84
11 Small 6 2, 2, 0 6.52 108.68 8.17 136.14
12 Medium 5 2, 2, 0 18.55 371.10 3.79 75.75
13 Half 5 2, 2, 0 4.55 91.07 8.04 160.73
14 Half 5 2, 2, 0 9.22 184.42 10.97 219.50
15 Medium 6 0.5, 0.5, 0 5.70 95.01 3.12 52.04
16 Small 6 2, 2, 0 14.00 233.35 7.90 131.72
17 Small 6 2, 2, 0 14.26 237.59 8.70 144.92
18 Small 5 2, 2, 0 17.75 354.99 7.32 146.49
19 Medium 5 0.5, 0.5, 0 2.47  49.43 3.56 71.10
20 Small 4 0.5, 0.5, 0 2.16 54.02 2.75 68.81
21 Small 5 0.5, 0.5, 0 1.85 37.08 15.85 317.05
22 Small 6 2, 2, 0 13.81 230.21 5.75 95.84
23 Medium 6 0.5, 0.5, 0 7.02 117.06 2.35 39.25
24 Medium 7 0.5, 0.5, 0 5.92 84.63 14.41 205.85
25 Medium 6 0.5, 0.5, 0 5.93 98.80 1.41 23.52
26 Medium 7 0.5, 0.5, 0 11.37 162.40 1.83 26.14
27 Medium 5 2, 2, 0 16.92 338.43 6.02 120.46
28 Half 5 2, 2, 0 8.91 178.19 4.74 94.73
29 Small 5 1, 1, 0 6.00 120.00 3.48 69.59
30 Small 5 1, 1, 0 11.36 227.20 1.91 38.11
Type of
applicators
Insertion
number
Size of
ovoids
Stepping
length (cm)
Prescribed
dose (Gy)
Prescription
point (x, y, z)
Rectum
dose (Gy)
Bladder
dose (Gy)
Maximum Relative Maximum Relative
Tandem
and
ovoids
31  Small 4 6 2, 2, 0 4.42 73.69 3.42 57.02
32 Small 4 6 2, 2, 0 5.07 84.56 2.36 39.40
33 Small 4 4 2, 2, 0 6.41 160.21 2.04 51.11
34 Small 4 4 2, 2, 0 4.23 105.67 7.50 187.57
35 Small 5 6 2, 2, 0 8.04 133.98 6.89 114.85
36 Small 5 5 2, 2, 0 10.08 201.66 0.76 15.15
37 Small 5 5 2, 2, 0 10.94 218.85 0.78 15.54
o
1
d
i
l
e
c38 Medium 4 5 
39 Medium 7 6 
40 Medium 7 6 
f TLD-100 (LiF:Mg, Ti, Harshaw/Bicron, Solon, OH) sized
 mm × 1 mm × 1 mm were employed for the purpose of blad-
er dose measurements.
For the rectum dosimetry, 10 TLD-400 chips were inserted
n a hollow sterile plastic tube designed to cover an overall
ength of the rectum equal to 12 cm.  0.9 mm long plastic spac-
rs were utilized to maintain the spacing between the ten
hips. The total length of the rectum tube was about 17 cm,2, 2, 0 2.80 56.07 4.57 91.50
2, 2, 0 6.75 112.43 2.89 48.19
2, 2, 0 9.90 165.01 4.26 71.00
including a 12 cm length containing 10 TLDs and an interval
of 5 cm including a plastic spacer without any TLD.
To measure bladder dose, three TLD-100 microcubes were
used. The microcubes were inserted in a hollow sterile plastic
tube designed for this purpose. The outer diameter of the tube
was 3.2 mm.  The total length of the bladder tube was 8 cm.  This
length was divided into two parts: the ﬁrst 5.5 cm space was
ﬁlled with a plastic spacer and the second part included three
356  reports of practical oncology and rad
Table 2 – Summary of measured rectum and bladder
dose relative to the prescribed dose.
Relative measured dose
to the prescribed dose (%)
Number of cases
Rectum Bladder
0–25% 0 5
25–50% 5 7
50–100% 11 13
100–200% 14 12
200–300% 7 2
have an impact on their treatment strategies in the future300–350% 1 1
350–400% 2 0
TLDs. Intervals of 1 cm were maintained by inserting plastic
spacers between the TLDs.
The tubes designed for the rectum and bladder were
inserted into the patients’ rectum and bladder before inser-
tion of the sources, when the applicators were being inserted.
The tubes were ﬁxed by attaching to the application set up.
4.  Results
4.1.  Dose–response  of  the  TLDs
The dose–response curves for the TLDs (type 400 and type 100)
are shown in Fig. 2. As evident from this ﬁgure, the dose given
to the TLDs was plotted versus measured dose over a dose
range of 1–20 Gy for the type 400 and 1–11 Gy for type 100 TLDs.
As evident from Fig. 1(a) for the TLD-400 chips, the slope of
the ﬁtted line to the data points (0.9691) is very close to unity.
So in our further measurements of rectum dose, the measured
dose by the TLD-400 chips, in the dose range of 1–20 Gy, could
be considered equal to the actual dose received by the TLDs.
For the TLD-100 microcubes, the following equation was ﬁtted
to the dose response data (Fig. 1(b)):
D = 0.7343 × (measured dose) + 0.641 (1)
Since the slope of the above linear function is different from
unity, in our further measurement of bladder dose, we have
utilized this equation to convert the measured dose by the
TLDs to the actual dose received by them. Reported bladder
doses in this work are converted dose values derived from Eq.
(1).
4.2.  In  vivo  measurements
The results of in vivo dose measurements during 40 sessions
of insertions are listed in Table 1. The table also includes the
treatment details for each session.
Percentage measured maximum rectal and bladder dose
of patients normalized to the dose at the point of dose pre-
scription was divided into different ranges. The results are
presented in Table 2. As evident in this table, the relative max-
imum dose to the rectum in 29 insertions (72.5% of treatments
sessions) and to bladder in 18 insertions out of 40 (45% of
treatments sessions) are higher than the value of 80%.iotherapy 1 7 ( 2 0 1 2 ) 352–357
5.  Discussion  and  conclusion
In this study, the dose to the rectum and bladder of cervical or
vaginal patients treated by a GZP6 brachytherapy unit were
measured. It has been recommended by the ICRU and the
American Brachytherapy Society that the maximum dose to
the rectum and bladder in intracavitary treatment of vaginal
or cervical cancer should be lower than 80% of the prescribed
dose to point A (point of dose prescription in the Manchester
system).5,11 In summary, our results showed that out of the
total number of 40 insertions, the maximum rectum dose in
29 insertions (72.5% of treatments sessions) and the maximum
bladder dose in 18 insertions (45% of treatments sessions)
were higher than the 80% of prescribed dose to the point of
dose prescription. This may be related to either the experi-
ence of cardiologists or to GZP6 treatment planning system.
A more  detailed study in this ﬁeld is required to illuminate
the cause. In brachytherapy departments, dose to the rec-
tum and bladder is determined during treatment planning
procedures by radiography, but there are studies reporting
discrepancies between radiography and in vivo measurement
methods.12–15 Since in vivo dosimetry is a method that esti-
mates dose to the rectum and bladder through measurements
in real conditions, in vivo measurement of rectum and blad-
der doses of patients for all therapeutic sessions could be
clinically useful. Performing patient dosimetry in each ses-
sion, in which the dose to the rectum and/or bladder may
be high, will provide an option to reduce the overall dose
to the rectum and/or bladder which is the summation of
doses over the sessions given to a particular patient. GZP6
treatment planning system has no option to deﬁne stepping
sources for ovoid applicators. It is not possible either to apply
time weighting for different dwell positions in the stepping
sources which are used in tandem applicators in this sys-
tem. However, there are other methods to reduce rectal and
bladder dose: using ovoids with shields, changing the treat-
ment plan, reducing the number of brachytherapy sessions,
etc. Although in this study, the averaged measured maximum
doses to the rectum and bladder were respectively 7.62 and
5.17 Gy, there are also other studies in which the identiﬁed
doses to these organs were higher than 5 Gy,13,16–18 which
is a common prescribed dose to point A in the Manchester
system.
The present retrospective study was based on the eval-
uation of brachytherapy treatments performed by a GZP6
afterloading system during a limited period of time at the
Reza Radiotherapy and Oncology Center. At the Reza Radio-
therapy and Oncology Center, the rectum and bladder doses
are not measured routinely but are calculated by radiographs.
Our results will encourage more  actions to reduce rectum
and bladder doses in this center, as well as other centers
in Iran which are using GZP6 unit. Following the publication
of our results, the treatment team in the Reza Radiotherapy
and Oncology Center and other radiotherapy centers in Iran
which are using this system may have an evaluation on the
treatments performed by the GZP6 unit. This evaluation willbrachytherapy practice involving the GZP6 afterloading sys-
tem.
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